Cohance Lifesciences, a company in the Pharmaceuticals industry, reported revenue of ₹477 crore and net profit of ₹2.27 crore for the September 2026 quarter.
Cohance Lifesciences (NSE: COHANCE) closed at ₹462.30 on 20 Nov 2026, down 20.6% over the past year. Its market capitalisation is ₹17,689 crore and it trades at 362.4 times earnings.
Cohance Lifesciences is a Hyderabad-based CDMO operating across pharmaceutical development, manufacturing, APIs, formulations and specialty chemicals. The company states that it features among the Top 20 CDMOs globally; its Pharma CDMO business works with 19 of the top 20 global innovators, while the API portfolio ranks among the top three suppliers in 8 of its top 10 molecules.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.